↓ Skip to main content

Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers

Overview of attention for article published in BMC Cancer, February 2016
Altmetric Badge

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
58 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers
Published in
BMC Cancer, February 2016
DOI 10.1186/s12885-016-2127-2
Pubmed ID
Authors

Lourdes Mengual, Juan José Lozano, Mercedes Ingelmo-Torres, Laura Izquierdo, Mireia Musquera, María José Ribal, Antonio Alcaraz

Abstract

Additional accurate non-invasive biomarkers are needed in the clinical setting to improve prostate cancer (PCa) diagnosis. Here we have developed a new and improved multiplex mRNA urine test to detect prostate cancer (PCa). Furthermore, we have validated the PCA3 urinary transcript and some panels of urinary transcripts previously reported as useful diagnostic biomarkers for PCa in our cohort. Post-prostatic massage urine samples were prospectively collected from PCa patients and controls. Expression levels of 42 target genes selected from our previous studies and from the literature were studied in 224 post-prostatic massage urine sediments by quantitative PCR. Univariate logistic regression was used to identify individual PCa predictors. A variable selection method was used to develop a multiplex biomarker model. Discrimination was measured by ROC curve AUC for both, our model and the previously published biomarkers. Seven of the 42 genes evaluated (PCA3, ELF3, HIST1H2BG, MYO6, GALNT3, PHF12 and GDF15) were found to be independent predictors for discriminating patients with PCa from controls. We developed a four-gene expression signature (HIST1H2BG, SPP1, ELF3 and PCA3) with a sensitivity of 77 % and a specificity of 67 % (AUC = 0.763) for discriminating between tumor and control urines. The accuracy of PCA3 and previously reported panels of biomarkers is roughly maintained in our cohort. Our four-gene expression signature outperforms PCA3 as well as previously reported panels of biomarkers to predict PCa risk. This study suggests that a urinary biomarker panel could improve PCa detection. However, the accuracy of the panels of urinary transcripts developed to date, including our signature, is not high enough to warrant using them routinely in a clinical setting.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 3%
Unknown 56 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 22%
Student > Master 9 16%
Student > Bachelor 7 12%
Student > Ph. D. Student 7 12%
Professor > Associate Professor 3 5%
Other 8 14%
Unknown 11 19%
Readers by discipline Count As %
Medicine and Dentistry 11 19%
Biochemistry, Genetics and Molecular Biology 10 17%
Agricultural and Biological Sciences 9 16%
Immunology and Microbiology 3 5%
Physics and Astronomy 2 3%
Other 5 9%
Unknown 18 31%